Main >> Labarai >> Haɗu da Ubrelvy, sabon magani da aka amince da shi na FDA wanda ke warkar da ƙaura

Haɗu da Ubrelvy, sabon magani da aka amince da shi na FDA wanda ke warkar da ƙaura

Labarai

A cikin kusan 1 a cikin gidaje 4 na Amurka, wani yana fama da ƙaura, a cewar Gidauniyar Binciken Migraine . Kuma da yawa daga cikin wadanda abin ya shafa ba su sami maganin da ke aiki ba. Yanzu, akwai sabon maganin ƙaura zaɓi a sararin sama Kwanan nan FDA ta amince da Ubrelvy (ubrogepant), magani wanda ke aiki cikin sauri don taimakawa rage tsawon ƙaura.

Menene ƙaura?

Migraine ba kawai mummunan ciwon kai ba. A gaskiya, ƙaura an kirga shi kamar cuta ta shida mafi nakasa a duniya. Baya ga tsananin ciwon kai, rikicewar gani, tashin zuciya, amai, jiri, matsananciyar hankali ga sauti, haske, taɓawa da ƙanshi, da raɗaɗi ko rauni a cikin tsaurara ko fuska galibi suna tare da ƙaura.

Dangantaka : Yaushe za ku yi magana da likitanku game da takardar likita don ƙaura

Yaya yawan ƙaura?

12% na yawan jama'a - ciki har da 10% na yara-suna fuskantar ƙaura. Suna shafar 18% na matan Amurka da 6% na maza. A cikin duka, wannan ya fi mutane miliyan 4 waɗanda ke da ƙaurar ƙaura ta yau da kullun kuma suna fuskantar fiye da kwanaki 15 na ƙaura a wata.

Maganin Ciwon Mara

Akwai magungunan likitanci da yawa da ke akwai don hana ƙaura, da kuma magance alamomin da zarar mutum ya fara. Bugu da kari, a wasu lokuta likitoci suna bayar da shawarar sauye-sauyen rayuwa (kamar rage damuwa ko rage hasken wuta), suna kwadaitar da marasa lafiya su dauki karfin NSAIDs kan-kan-kan-kudi ko kuma takardar magani ibuprofen ) don gudanar da ciwo, tsara magungunan antipsychotics, antidepressants, antiepileptic drugs, beta blockers, har ma da ba marasa lafiya shawara su karɓa Allurar Botox don rage yawaita da alamomin ƙaurarsu.

Dangantaka : Shin yakamata ku ɗauki Topamax don ƙaura?

Menene Ubrelvy (ubrogepant)?

Ubrelvy (ubrogepant) shine sabon magani na ƙaura (tare da ko ba tare da aura ba). Yana da sabon magani, ma'ana, shine karo na farko da aka yarda da wannan rukunin magungunan don magance ƙaura. Wannan na iya zama canjin rayuwa ga marasa lafiya waɗanda ba su sami sauƙi daga magungunan da ake da su ba.

Magungunan da FDA ta amince da su an tabbatar da su a asibiti don rage tsawon lokutan ƙaura, tare da rage ciwo da alamomin da ke tattare da su. Yana aiki ta hanyar toshe tasirin mai karɓar mai karɓar peptide (CGRP) mai haɗari. An tabbatar da CGRP a matsayin abu ɗaya na ciki wanda ke haifar da kiyaye ƙaura. Kuma kodayake akwai wasu magungunan Allurai da sunan Aimovig , Rashin daidaito , da Ajovy —Wannan hana ƙaura ta hanyar toshe CGRP, Ubrelvy ya ware saboda magani ne na baka wanda ke aiki don warkar da ƙaura idan sun riga sun faru. Ya zo tare da zaɓuɓɓukan allurai guda biyu (50 da 100 mg mg) don samar da sassauƙa don buƙatun marasa lafiya da kuma inganta tasiri ga mafi yawan jama'a.

Ubrelvy ya wuce gwaji da gwaje-gwaje na asibiti, wanda ya haifar da amincewarsa ta ƙarshe daga gudanarwa. A cewar FDA, an nuna tasirin magungunan a cikin bazuwar biyu, makafi biyu, gwajin-wuribo. Yayin karatun, marasa lafiya 1,439 da ke da tarihin ƙaura (tare da ba tare da aura ba) sun karɓi maganin Ubrelvy da aka yarda da su don magance ƙaura mai ci gaba.

A cikin karatun biyu, kimanin 19% na marasa lafiya sun ba da rahoton rashin jin zafi sa'o'i biyu bayan jiyya (wanda aka bayyana a matsayin raguwa da tsananin ciwon kai daga matsakaici ko ciwo mai zafi ba ciwo ba) kuma 38.6% sun ba da rahoton jin cikakken taimako daga mafi mawuyacin halin da suke fama da cutar ƙaura , hasken hankali, ko sautin sauti) awa biyu bayan jiyya. Wadannan kashi-kashi suna da matukar mahimmanci tsakanin marasa lafiya masu karɓar Ubrelvy (a kowane fanni) idan aka kwatanta da waɗanda suka karɓi placebo.

Abubuwan da aka fi sani da Ubrelvy sune tashin zuciya da rashin ƙarfi (gajiya).

Kamar yadda mai magana da yawun farko, Ubrelvy ya ba da wani sabon nau'in magani na daban don mutanen da ke dauke da ciwo mai raunin gaske da sauran alamomin cutar ta ƙaura, David Nicholson, mataimakin shugaban zartarwa da babban jami'in R&D na kamfanin lasisi na Ubrelvy, Allergan, ya ce a cikin latsa sanarwa . Gudanar da maganganunta tare da ƙarfin kashi biyu yana ba da damar sassaucin magani da sauƙi lokacin da harin ƙaura ya auku. Yayin da muke ci gaba da fitar da kere-kere a cikin kula da ciwon kaura, muna alfahari da baiwa marasa lafiya wani zabi, kuma muna da yakinin cewa zai kawo canji ga wadanda suke bukata. A Allergan, munyi imanin cewa marasa lafiyar ƙaura sun cancanci samun duk sababbin magunguna don wannan cuta mai rauni.